We're now on Bluesky! 🌟 Follow us for the latest in oncology research, expert insights, and journal updates—now across platforms. 🔗 Join us on Bluesky: #Oncology #CancerResearch #MedicalScience

#TopReadTuesday from TAM:. Pembrolizumab improves outcomes in triple-negative breast cancer but can rarely cause immune-related nephrotoxicity. This case highlights AKI recognition, prompt steroid treatment, and full renal recovery without biopsy. 🔗

Join millions who have switched to Grok.

Thanks to Franziska Geissler, Ksenija Nesic, @OKondrashova1, Alexander Dobrovic, Matthew J. Wakefield, @SwisherLiz & @ProfClareScott, for this in‑depth review on the clinical relevance and pitfalls of assessing DNA methylation in cancer. #CancerEpigenetics #Oncology.

#TopReadTuesday from TAM:. Aberrant DNA methylation is a hallmark of cancer, driving initiation, progression & therapy resistance. This review details clinical impacts from MMR gene silencing to BRCA1 methylation loss under treatment pressure. 🔗

In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved. These findings support a synergistic role for RT with immunotherapy. 🔗

In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo). FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option.

New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165):.🔹 Similar MMR at 12 mo (85.1% vs 88.2%).🔹 Nilotinib led to higher MR4 at all timepoints.🔹 Flumatinib had fewer metabolic/liver AEs. 🔗

In mRCC, second-line ICI vs TKI showed similar OS (44.8 vs 41.1 mo; p=0.446). But in NLR-high patients, TKI→ICI led to better survival vs TKI→TKI. Bone mets and nephrectomy history also influenced outcomes. 👉 NLR may guide 2L therapy: .

In a cohort of 514 cancers, high ICOS expression (14%) was linked to elevated PD-1, PD-L1 & CTLA-4 RNA (all p<0.05) but not survival in ICI-treated or immunotherapy-naïve patients. Suggests ICOS ≠ prognostic, but may guide combo ICI strategies.

📌 In a Chinese LCNEC cohort (n=151), median OS was 17.8 mo. Adjuvant chemo post-surgery reduced distant spread & improved 2-yr OS (37.1% vs 79.9%, p<0.001). Immunochemotherapy outperformed chemo alone in advanced disease.

📊 In non-resectable stage III melanoma, T-VEC and IL-2 showed no significant differences in PFS (5.0 mo), OS (34.0 mo), or response rates. Both were well tolerated with minimal AEs. Real-world data to guide intralesional therapy choice.

3 patients with metastatic KRAS-wildtype PDAC showed prolonged response to osimertinib after EGFR exon 19 deletion was found via NGS. Early molecular & metabolic responses seen; disease controlled for 6, 8, and 17 months. A case for rare mutation testing.

First reported case of coma from luminal breast cancer brain mets reversed without radiation: patient treated w/ nasogastric abemaciclib + fulvestrant post-surgery. Seizures resolved, imaging improved, full functional recovery—patient returned to work.

Thanks to @LandonLChan and Stephen L. Chan for this expert look at the evolving future of immunotherapy in hepatocellular carcinoma.

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications. Read here:

3️⃣ Is innovation sustainable? A look at lazertinib. This cost-effectiveness analysis questions the long-term value of lazertinib for EGFR-mutated lung cancer—and what price point makes it viable in real-world settings. 📄 #LungCancer #HealthEconomics.

2️⃣ Rare cancers, real-world challenges. How can advocacy improve outcomes in low- and middle-income countries? This perspective from Brazil highlights how the Desmoid Tumor Association is reshaping access to care. 📄 #RareCancer #GlobalOncology.

1️⃣ Beyond Chemotherapy: The next generation of ADCs. Antibody–drug conjugates (ADCs) are evolving. This review explores novel payloads—from PROTACs to radioactive isotopes—designed to enhance specificity and reduce toxicity. 📄 #Oncology #ADCs.

🧵April is National Cancer Control Month. At @TAMedOncol, we're highlighting research that reflects commitment to improving cancer care—through innovative therapies, cost-effectiveness, and global equity. Here are some articles from the past year ⬇️.

Thanks to Sora Kang and EB member Sung-Bae Kim for this essential overview—highlighting not just T-DXd and SG, but novel ADCs in the pipeline. 📘 Part of our Special Collection on ADCs in Breast Oncology:.

🔍 A new review explores the toxicity profiles and management strategies of emerging antibody–drug conjugates (ADCs) in breast cancer. From ILD to neutropenia, understanding these effects is key to maximizing benefit across all BC subtypes. Read here: